Narcolepsy
Conditions
Interventions
case group (medication regimen recommended by guidelines):None
control group:None
Sponsors
The People's Hospital of Guangxi Zhuang Autonomous Region
Eligibility
Sex/Gender
All
Age
6 Years to 17 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for the case group: aged 6–17 years, meeting the diagnostic criteria for NT1/NT2 as outlined in the Chinese Guidelines for the Diagnosis and Treatment of Narcolepsy (2022 edition), with informed consent from both parents and children. Inclusion criteria for the control group: 1 Parents and children self-reported good health status with no history of major chronic diseases. 2 Parents reported no sleep-related issues in children, such as nighttime snoring, apnea, or excessive daytime sleepiness.
Exclusion criteria
Exclusion criteria: Exclusion criteria for the case group: 1 Diagnosed neurological disorders, mental disorders, or developmental behavioral disorders (e.g., epilepsy, ADHD, depression, etc.). 2 Presence of severe chronic diseases. 3 Severe physical diseases that may affect sleep (e.g., asthma, heart disease, severe obesity, immune system disorders). 4 Long-term use of medications affecting sleep or the central nervous system within the past 3 months. 5 Recent (within 1 month) acute infection or vaccination, or previous immunosuppressive/immunomodulatory therapy. Exclusion criteria for the control group: 1 Any sleep disorder diagnosed or suggested by physician screening (including insomnia, sleep apnea, etc.). 2 History of cataplexy, sleep paralysis, or hypnagogic hallucinations. 3 Presence of severe chronic diseases. 4 Diagnosed neurological disorders, mental disorders, or developmental behavioral disorders (e.g., epilepsy, ADHD, depression, etc.). 5 Severe physical diseases that may affect sleep (e.g., asthma, heart disease, severe obesity, immune system disorders). 6 Long-term use of medications affecting sleep or the central nervous system within the past 3 months. 7 Recent (within 1 month) acute infection or vaccination, or previous immunosuppressive/immunomodulatory therapy. 8 Any other conditions deemed unsuitable for participation in this study by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| sleep quality;clinical scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| quality of life ;imaging data;humoral biochemistry; | — |
Countries
China
Contacts
Public ContactZhao Mingming
The People's Hospital of Guangxi Zhuang Autonomous Region
Outcome results
None listed